Please select the option that best describes you:
What is your experience with liposomal-encapsulated daunorubicin and cytarabine (CPX-351) for first line treatment of therapy-related AML or AML with myelodysplasia-related changes in elderly patients?
Do you have experience administering these agents in the outpatient setting?
Answer from: Medical Oncologist at Academic Institution
Our center has been administering CPX-351 to outpatients for the last few months. We monitor the patient closely in the first week for tumor lysis. Since the neutropenic fever rate is the same as 7&3 we have need to admit many of the patients at some point in the cycle but overall it has g...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Outpatient therapy feasible, but practically difficult in elderly patients with transfusion requirements, invariable NF and some delay in count recovery. Had trouble even with consolidation doses.